Statins might protect against glaucoma.
Quoted:
New research in the British Journal of Ophthalmology showed that people who take cholesterol-lowering statins have a lower risk of developing glaucoma. What's more, glaucoma patients already on statins needed fewer interventions — such as surgery or pressure-reducing drops — than those not taking the drug.
The findings offer an exciting glimpse into potential new ways to preserve sight.
"If confirmed through additional research, these findings could eventually lead to a complementary strategy for glaucoma treatment," said senior study author Robert Weinreb, MD, distinguished professor in the Viterbi Family Department of Ophthalmology at UC San Diego School of Medicine and ophthalmologist at UC San Diego Health. "Certainly, patients with statins were protected from development to glaucoma, from worsening of glaucoma, so in a patient who's already being treated for glaucoma, it could reduce the likelihood of progression."
Weinreb and his team analyzed data from more than 200,000 statin users older than 40 years against a control group of the same size. Those on statins were 15% less likely to develop open-angle glaucoma over 5 years — and 10% less likely over a decade.
In a comparison of nearly 280,000 glaucoma patients, those taking statins required far fewer invasive procedures: They were 60% less likely to need an in-office laser procedure, 55% less likely to need minimally invasive glaucoma surgery, and 36% less likely to undergo conventional surgery. Statin use was also linked to a reduced need for daily pressure-lowering eye drops.
The potential mechanism remains unclear, but Weinreb pointed to prior research suggesting the drugs carry powerful anti-inflammatory, immune-modulating, and neuroprotective properties.
That last piece — neuroprotection — may be critical. Neuroprotective strategies represent one of the most promising frontiers in modern eye care. Rather than simply lowering eye pressure, they aim to directly shield the eye's specialized nerve cells, known as retinal ganglion cells, from dying off early. For example, biotechnology company Life Biosciences is studying an epigenetic therapy designed to reset cellular gene expression patterns and restore function in retinal ganglion cells in patients with glaucoma.
Because the optic nerve relies on robust blood flow, a patient's cardiovascular and metabolic health may affect how vulnerable they are to sight loss.
Cardiovascular factors such as high cholesterol, hypertension, and diabetes have been shown to influence glaucoma risk. If future clinical trials confirm statins' protective role, Jammal believed it would give doctors a clear roadmap for when and how to add statins to a patient's vision-saving regimen. Given their low cost and established safety profile, statins could become an even more compelling choice for patients who already meet the criteria for cholesterol management.





